Latest Pneumococcal vaccine Stories
WASHINGTON, Nov. 17, 2010 /PRNewswire/ -- New data from the Centers for Disease Control and Prevention (CDC) show that adults remain largely unvaccinated against preventable infectious illnesses. At a news conference convened today by the National Foundation for Infectious Diseases (NFID), experts in public health, infectious disease, oncology and other medical specialties discussed the data and the health consequences for adults who skip vaccines. They collectively called on all adults and...
CHICAGO, Nov. 16, 2010 /PRNewswire/ -- VaxTrac announced today that it has received a US$100,000 Grand Challenges Explorations grant from the Bill & Melinda Gates Foundation. The grant will support an innovative global health research project conducted by Mark Thomas, Executive Director, titled "VaxTrac Pilot Program 1 Narnaul, India." VaxTrac's project is one of 65 grants announced by the Gates Foundation in the fifth funding round of Grand Challenges Explorations, an initiative to...
Urgent action needed in the 15 countries responsible for three-quarters of child pneumonia deathsA Pneumonia Report Card released today by the International Vaccine Access Center (IVAC) on behalf of the Global Coalition against Child Pneumonia reveals where urgent efforts are needed to reach target levels of coverage for the life-saving interventions that can prevent, protect against and treat pneumonia in children.Pneumonia is the world's leading infectious killer of young children, taking...
Dramatic advance in understanding of how the body fights bacteria paves way for more effective vaccinesA new breakthrough in the fight against pneumonia, meningitis and septicaemia has been announced today by scientists in Dublin and Leicester.The discovery will lead to a dramatic shift in our understanding of how the body's immune system responds to infection caused by Streptococcus pneumoniae and pave the way for more effective vaccines.The collaborative research, jointly led by Dr Ed...
DALLAS, November 3, 2010 /PRNewswire/ -- ReportsandReports announces it will carry European Vaccine Markets Research Report in its store. Browse the complete Report on: http://www.reportsnreports.com/Reports/38156-european-vaccine-markets.html Browse All Manufacturing & Construction Reports: http://www.reportsnreports.com/market-research/medical-devices/ Browse All Kalorama Research Reports at http://www.reportsnreports.com/publishers/kalorama-information/ The...
Only a limited number of Streptococcus pneumoniae serotypes cause most invasive pneumococcal disease worldwideContrary to current thinking, the group of serotypes of Streptococcus pneumoniae responsible for most invasive pneumococcal disease worldwide is conserved across regions. Streptococcus pneumoniae is the leading bacterial cause of pneumonia, sepsis, and meningitis in children, which together comprise more than 25% of the 10 million deaths estimated to have occurred in 2000 in children...
Infants who received heptavalent pneumococcal conjugate vaccination (PCV-7) at 2, 4, and 11 months were more likely than unvaccinated controls to have nasopharyngeal (in the nasal passages and upper part of the throat behind the nose) acquisition of pneumococcal serotype 19A, a leading cause of respiratory pneumococcal disease, according to a study in the September 8 issue of JAMA."A rapid increase in the presence of pneumococcal serotype 19A strains that are often multiresistant to...
The number of children admitted to English hospitals with bacterial pneumonia decreased by a fifth in the 2 years following the introduction of a vaccine to combat the diseaseThe number of children admitted to English hospitals with bacterial pneumonia decreased by a fifth in the two years following the introduction of a vaccine to combat the disease, according to a new study published August 27 in the journal Thorax.Bacterial pneumonia is a serious illness caused by Streptococcus pneumoniae...
NEW YORK, Aug. 23 /PRNewswire-FirstCall/ -- The World Health Organization (WHO) has granted prequalification to Prevenar 13* (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed])for active immunization of infants and children from 6 weeks through five years of age against invasive disease, pneumonia and otitis media caused by the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) contained in the vaccine. WHO prequalification allows for the...
The GAVI Alliance and Johns Hopkins Bloomberg School of Public Health celebrate new vaccine era; applaud Baltimore's efforts to immunize every child; call for resources to do the same worldwideA Johns Hopkins University scientist, whose team of researchers recently identified pneumonia, diarrhea, and malaria as the primary causes of death of 6 million of the world's poorest children, today called on leaders in donor and developing nations to take action to address the terrible death...
